Stages Stage and grade mean different things. Grade describes how the cancer cells look and how they may act. Stage describes how deeply the tumor has grown into the bladder lining. Both help guide treatment. NMIBC includes stages 0a, 0is and 1. In these stages, the cancer has not grown into the bladder muscle. Stage 0a, noninvasive papillary cancer, also called Ta. The tumor has stayed in the bladder lining. Stage 0is, carcinoma in situ (CIS), also called Tis. CIS is a flat, high-grade cancer in the bladder lining. Stage 1, T1 bladder cancer. The cancer has grown into tissue under the bladder lining but has not reached the muscle layer. Solicite una consulta Diagnósticos y tratamientosSurvival rates Sept. 10, 2026 Comparte en: FacebookTwitter Living with non-muscle-invasive bladder cancer? Connect with others like you for support and answers to your questions in the Bladder Cancer support group on Mayo Clinic Connect, a patient community. Bladder Cancer Discussions What experience has anyone had with the Signatera blood test? 172 Replies Wed, Oct 21, 2026 chevron-right Anyone had gemcitabine and docetaxel for Bladder Cancer? 154 Replies Tue, Oct 20, 2026 chevron-right First BCG treatment: What to expect? 45 Replies Thu, Sep 17, 2026 chevron-right See more discussions Mostrar referencias Flaig TW, et al. Bladder cancer, version 1.2026, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2026; doi:10.6004/jnccn.2026.0022. Holzbeierlein JM, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. Journal of Urology. 2024; doi:10.1097/JU.0000000000003846. Bladder cancer stages. National Cancer Institute. https://www.cancer.gov/types/bladder/stages. Accessed Aug. 27, 2026. Bladder cancer diagnosis. National Cancer Institute. https://www.cancer.gov/types/bladder/diagnosis. Accessed Aug. 27, 2026. Treatment of bladder cancer by stage. National Cancer Institute. https://www.cancer.gov/types/bladder/treatment/by-stage. Accessed Aug. 27, 2026. Bladder cancer — Cancer stat facts. Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed Aug. 27, 2026. Narayan VM, et al. Efficacy of intravesical nadofaragene firadenovec for patients with bacillus Calmette-Guérin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial. Journal of Urology. 2024; doi:10.1097/JU.0000000000004020. Necchi A, et al. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): A single-arm, multicentre, phase 2 trial. The Lancet Oncology. 2024; doi:10.1016/S1470-2045(24)00178-5. Guerrero-Ramos F, et al. Predicting recurrence and progression in patients with non-muscle-invasive bladder cancer: Systematic review on the performance of risk stratification models. Bladder Cancer. 2022; doi:10.3233/BLC-220055. EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). European Association of Urology. https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer. Accessed Aug. 27, 2026. Bladder cancer treatment (PDQ) — Health professional version. National Cancer Institute. https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq. Accessed Aug. 12, 2026. Bladder cancer prognosis and survival rates. National Cancer Institute. https://www.cancer.gov/types/bladder/survival. Accessed Aug. 12, 2026. Non-muscle-invasive bladder cancerSíntomasycausasDiagnósticosytratamientosStagesSurvivalratesMédicosydepartamentos CON-20607243 Enfermedades y afecciones Non-muscle invasive bladder cancer